The Virome in Early Life and Childhood and Development of Islet Autoimmunity and Type 1 Diabetes: A Systematic Review and Meta-analysis of Observational Studies
Overview
Affiliations
Viruses are postulated as primary candidate triggers of islet autoimmunity (IA) and type 1 diabetes (T1D), based on considerable epidemiological and experimental evidence. Recent studies have investigated the association between all viruses (the 'virome') and IA/T1D using metagenomic next-generation sequencing (mNGS). Current associations between the early life virome and the development of IA/T1D were analysed in a systematic review and meta-analysis of human observational studies from Medline and EMBASE (published 2000-June 2020), without language restriction. Inclusion criteria were as follows: cohort and case-control studies examining the virome using mNGS in clinical specimens of children ≤18 years who developed IA/T1D. The National Health and Medical Research Council level of evidence scale and Newcastle-Ottawa scale were used for study appraisal. Meta-analysis for exposure to specific viruses was performed using random-effects models, and the strength of association was measured using odds ratios (ORs) and 95% confidence intervals (CIs). Eligible studies (one case-control, nine nested case-control) included 1,425 participants (695 cases, 730 controls) and examined IA (n = 1,023) or T1D (n = 402). Meta-analysis identified small but significant associations between IA and number of stool samples positive for all enteroviruses (OR 1.14, 95% CI 1.00-1.29, p = 0.05; heterogeneity χ = 1.51, p = 0.68, I = 0%), consecutive positivity for enteroviruses (1.55, 1.09-2.20, p = 0.01; χ = 0.19, p = 0.91, I = 0%) and number of stool samples positive specifically for enterovirus B (1.20, 1.01-1.42, p = 0.04; χ = 0.03, p = 0.86, I = 0%). Virome analyses to date have demonstrated associations between enteroviruses and IA that may be clinically significant. However, larger prospective mNGS studies with more frequent sampling and follow-up from pregnancy are required to further elucidate associations between early virus exposure and IA/T1D.
Mpakosi A, Sokou R, Theodoraki M, Iacovidou N, Cholevas V, Tsantes A Diagnostics (Basel). 2025; 15(4).
PMID: 40002565 PMC: 11854275. DOI: 10.3390/diagnostics15040413.
Liu R, Zhang J, Chen S, Xiao Y, Hu J, Zhou Z Diabetes Obes Metab. 2024; 27(3):1045-1064.
PMID: 39618164 PMC: 11802406. DOI: 10.1111/dom.16101.
Immunological and virological triggers of type 1 diabetes: insights and implications.
Lemos J, Hirani K, von Herrath M Front Immunol. 2024; 14:1326711.
PMID: 38239343 PMC: 10794398. DOI: 10.3389/fimmu.2023.1326711.
Enteroviral infections are not associated with type 2 diabetes.
Liu H, Geravandi S, Grasso A, Sikdar S, Pugliese A, Maedler K Front Endocrinol (Lausanne). 2023; 14:1236574.
PMID: 38027145 PMC: 10643152. DOI: 10.3389/fendo.2023.1236574.
Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial.
Krogvold L, Mynarek I, Ponzi E, Mork F, Hessel T, Roald T Nat Med. 2023; 29(11):2902-2908.
PMID: 37789144 PMC: 10667091. DOI: 10.1038/s41591-023-02576-1.